The questions
I expect to be asked.

I am building a drug-development company. Bemitil is off-patent, but that does not make it a legal US dietary ingredient. A new dietary ingredient requires an NDI notification and the relevant eligibility assessment; an NDI notification does not authorize drug claims. The selected route is IND-led drug development.

Soviet-era origin does not establish a verified commercial history or explain a development decision. [RUSSIAN COMMERCIAL HISTORY: verified source and account]. My investment case is the experiment we can run now.

Historical reports do not settle causality. I want controlled functional testing with authenticated material, thresholds locked in advance, and independent confirmation. If the functional signal fails replication, candidate advancement stops.

I work as a merchant mariner in heat and adverse conditions. I bring banking and commodities experience and built Molekul.io to organize the research. That explains my focus. It does not replace a scientific lead, a contracted lab, or development experience. Those are early hiring and execution requirements.

I stop candidate advancement. I do not rebrand a failed heat result as a proven cognition or recovery product. Chlodantane, dalargin, and ME/CFS recovery remain separate follow-on concepts.

Heat gives the first program one functional question: does bemitil preserve work capacity under heat? Historical human heat reports and the military heat burden justify asking it. Human efficacy is unproven. I want the program to answer one question before expanding.

It protects against continuing candidate advancement after failed replication or unacceptable safety. It also prevents a molecular signal from substituting for a useful functional result. Numerical thresholds must be locked in months 0–3 by scientific leadership.

It funds an illustrative 18-month preclinical program: functional pharmacology and PK; molecular profiling; authenticated material and formulation; initial safety; scientific leadership and personnel; AI and evidence data; IP and regulatory work; and operations and contingency. It does not buy an approved product or a government contract. The allocation is a planning budget, not contracted quotes.